Stockreport
Biogen Inc. (BIIB) Gets Upgraded by UBS on Upcoming Pipeline Catalysts [Yahoo! Finance]
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
Neutral by UBS, with the firm adjusting the price target on the stock to $225 from $185. It told investors in a research note that it has increased conviction on the company's pipeline catalysts coming over the next 12-15 months, adding that the readouts should move the stock higher going into 2027. Biogen Inc. (BIIB): Among Small-Cap Healthcare Stocks Hedge Funds is Buying UBS also stated that it sees upside on the BIIB080 tau data this summer, adding that the “real upside catalyst” in fiscal Q4 is the Phase III litifilimab data in systemic lupus. It contended that Biogen Inc. (NASDAQ:BIIB) offers a “window of pipeline catalysts” and is an “under-owned out-of- favor stock that trades at a discount to large-cap peers”. In a separate development, Wells Fargo upgraded Biogen Inc. (NASDAQ:BIIB) to Overweight from Equal Weight on April 20, lifting the price target on the stock to $250 from $200. Biogen Inc. (NASDAQ:BIIB) is a global biopharmaceutical company that discovers, develo
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BIIB | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BIIB alerts
BIIB alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
NEWS
NEWS
- Biogen (BIIB) had its price target raised by Morgan Stanley from $190.00 to $200.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- High Growth Tech Stocks To Watch In Asia April 2026 [Yahoo! Finance][Yahoo! Finance]
- Biogen (BIIB) had its price target raised by The Goldman Sachs Group, Inc. from $231.00 to $238.00. They now have a "buy" rating on the stock.[MarketBeat]
- Biogen (BIIB) had its price target raised by Rothschild & Co Redburn from $150.00 to $180.00. They now have a "neutral" rating on the stock.[MarketBeat]
- Biogen (BIIB) had its price target raised by JPMorgan Chase & Co. from $175.00 to $185.00. They now have a "neutral" rating on the stock.[MarketBeat]
- More
BIIB
SEC Filings
SEC Filings
- 4/29/26 - Form SCHEDULE
- 4/29/26 - Form 10-Q
- 4/29/26 - Form 8-K
- BIIB's page on the SEC website
- More